Now showing items 1-10 of 10

    • The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy 

      Zhu, Di; Wang, Zhongqiu; Zhao, Jian-Jun; Calimeri, Teresa; Meng, Jiang; Hideshima, Teru; Fulciniti, Mariateresa; Kang, Yue; Ficarro, Scott; Tai, Yu-Tzu; Hunter, Zachary; McMilin, Douglas; Tong, Haoxuan; Mitsiades, Constantine S.; Wu, Catherine; Treon, Steven; Dorfman, David M.; Pinkus, Geraldine; Munshi, Nikhil; Tassone, Pierfrancesco; Marto, Jarrod; Anderson, Kenneth; Carrasco, Ruben D. (2015)
      B-cell malignancies frequently colonizes the bone marrow (BM). The mechanisms responsible for this preferential homing are not entirely known. Using multiple myeloma (MM) as a model of a terminally differentiated B-cell ...
    • Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma 

      Wu, Hong; Wang, Wenchao; Liu, Feiyang; Weisberg, Ellen L.; Tian, Bei; Chen, Yongfei; Li, Binhua; Wang, Aoli; Wang, Beilei; Zhao, Zheng; McMillin, Douglas W.; Hu, Chen; Li, Hong; Wang, Jinhua; Liang, Yanke; Buhrlage, Sara J.; Liang, Junting; Liu, Jing; Yang, Guang; Brown, Jennifer R.; Treon, Steven P.; Mitsiades, Constantine S.; Griffin, James D.; Liu, Qingsong; Gray, Nathanael S. (American Chemical Society, 2014)
      BTK is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases. We have used structure-based drug design in conjunction with kinome profiling ...
    • An epigenomic approach to therapy for tamoxifen-resistant breast cancer 

      Feng, Qin; Zhang, Zheng; Shea, Martin J; Creighton, Chad J; Coarfa, Cristian; Hilsenbeck, Susan G; Lanz, Rainer; He, Bin; Wang, Lei; Fu, Xiaoyong; Nardone, Agostina; Song, Yongcheng; Bradner, James; Mitsiades, Nicholas; Mitsiades, Constantine S; Osborne, C Kent; Schiff, Rachel; O'Malley, Bert W (Nature Publishing Group, 2014)
      Tamoxifen has been a frontline treatment for estrogen receptor alpha (ERα)-positive breast tumors in premenopausal women. However, resistance to tamoxifen occurs in many patients. ER still plays a critical role in the ...
    • High-throughput approaches to discover novel immunomodulatory agents for cancer 

      McMillin, Douglas William; Mitsiades, Constantine S (Landes Bioscience, 2012)
      The clinical success of immunomodulatory thalidomide derivatives has renewed the general interest in immunomodulatory anticancer compounds and prompted us to develop a high-throughput system to quantify immune effector-cell ...
    • Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease 

      Dowling, Paul; Hayes, Catriona; Ting, Kay Reen; Hameed, Abdul; Meiller, Justine; Mitsiades, Constantine; Anderson, Kenneth C; Clynes, Martin; Clarke, Colin; Richardson, Paul; O’Gorman, Peter (BioMed Central, 2014)
      Background: Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma ...
    • Lenalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma 

      Görgün, Güllü; Nijhof, Inger S; Raymakers, Reinier A; Lokhorst, Henk M; Groen, Richard W.j.; Jakubikova, Jana; Mitsiades, Constantine S; Hideshima, Teru; Laubach, Jacob; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl; van de Donk, Niels WCJ (Dove Medical Press, 2012)
      Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with ...
    • The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms 

      Richardson, Paul Gerard Guy; Laubach, Jacob; Schlossman, Robert Lawrence; Ghobrial, Irene; Mitsiades, Constantine S; Rosenblatt, Jacalyn Mara; Mahindra, Anuj; Raje, Noopur; Munshi, Nikhil C; Anderson, Kenneth Carl (Blackwell Publishing Ltd, 2011)
      Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related ...
    • Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells 

      Weisberg, Ellen; Liu, Qingsong; Zhang, Xin; Nelson, Erik; Sattler, Martin; Liu, Feiyang; Nicolais, Maria; Zhang, Jianming; Mitsiades, Constantine S; Smith, Robert Walsh; Stone, Richard; Galinsky, Ilene; Nonami, Atsushi; Griffin, James D.; Gray, Nathanael (Public Library of Science, 2013)
      Objectives: Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell reduction, however a marginal decrease in bone marrow blasts. This ...
    • Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ 

      Reagan, Michaela Ruth; Seib, F. Philipp; McMillin, Douglas William; Sage, Elizabeth K.; Mitsiades, Constantine S.; Janes, Sam M.; Ghobrial, Irene; Kaplan, David L. (Korean Breast Cancer Society, 2012)
      Purpose Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based ...
    • Targeting transcription regulation in cancer with a covalent CDK7 inhibitor 

      Kwiatkowski, Nicholas; Zhang, Tinghu; Rahl, Peter B; Abraham, Brian J; Reddy, Jessica; Ficarro, Scott B; Dastur, Anahita; Amzallag, Arnaud; Ramaswamy, Sridhar; Tesar, Bethany; Jenkins, Christopher R; Hannett, Nancy M; McMillin, Douglas; Sanda, Takaomi; Sim, Taebo; Kim, Nam Doo; Look, Thomas; Mitsiades, Constantine; Weng, Andrew P; Brown, Jennifer R; Benes, Cyril H.; Marto, Jarrod A; Young, Richard A; Gray, Nathanael S. (2014)
      Tumor oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state1, but direct pharmacological inhibition of transcription factors has thus far proven difficult2. ...